Return to homepagePandemic Pact

APEPTICO Research and Development GmbH

  • Funded by Austrian Research Promotion Agency (FFG)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Austrian Research Promotion Agency (FFG)

  • Research Location

    Austria

  • Lead Research Institution

    Apeptico (Austria)

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Apeptico has developed the active ingredient Solnatide for the acute and therapeutic treatment of patients with moderate to severe acute respiratory distress syndrome (ARDS). The orally inhaled substance Solnatide has demonstrated clinical efficacy in a phase I and in two phase II clinical studies in ARDS patients. The use of Solnatide is now being investigated in a clinical study for its effectiveness in Covid patients.